Who is the manufacturer of Mobosetinib and is it effective?

Mobocertinib is an irreversible EGFR inhibitor based on indole-pyrimidine, developed by Takeda Pharmaceuticals. The drug was approved in the U.S. in September 2021 for the treatment of adult patients with EGFR ex20ins-mutated locally advanced or metastatic non-small cell lung cancer who have disease progression during or after standard treatment with platinum-based chemotherapy.

The approval of mobosetinib marks the first oral small molecule EGFR TKI for the treatment of EGFR ex20ins-positive non-small cell lung cancer. The FDA approval was based on results from the platinum-pretreated population of the Phase 1/2 trial of mobosertinib, which included 114 patients with EGFR exon 20 insertion+ non-small cell lung cancer who had previously received platinum-based therapy and received the 160 mg dose. Results from the phase 1/2 trial were an objective response rate (ORR) of 28%, a median duration of response (DoR) of 17.5 months, a median overall survival (OS) of 24 months, and a median progression-free survival (PFS) of 7.3 months.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.